Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd Issues Q2 2013 Earnings Guidance Below Analysts' Estimates; Issues FY 2013 EBITDA And EPS Guidance Above Estimates; Issues FY 2013 Net Income Guidance Below Estimates


Thursday, 9 May 2013 04:01pm EDT 

Salix Pharmaceuticals Ltd announced that for second quarter of 2013, it expects GAAP net income of $31.5 million, EBITDA of $84.5 million, adjusted Non-GAAP net income of $50.0 million and adjusted Non-GAAP net income per share, fully diluted of $0.78. For fiscal 2013, it expects GAAP net income of $144.0 million, EBITDA of $368.0 million, adjusted Non-GAAP net income of $215.0 million and adjusted Non-GAAP net income per share, fully diluted of $3.37. According to I/B/E/S Estimates, analysts are expecting the Company to report EBITDA of $85 million, net income of $80 million and EPS of $0.79 for second quarter of 2013; EBITDA of $363 million, net income of $216 million and EPS of $3.36 for fiscal 2013. 

Company Quote

159.89
4.02 +2.58%
17 Sep 2014